Methylprednisolone IV Pulse (Nephrology)
Brand names: Solu-Medrone
Intravenous pulse methylprednisolone is a high-potency glucocorticoid regimen used in nephrology to induce rapid immunosuppression in severe glomerular and immune-mediated renal disease, such as crescentic glomerulonephritis and vasculitis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
As a synthetic corticosteroid, it binds glucocorticoid receptors to broadly suppress inflammatory and immune responses, reducing cytokine production and inflammatory cell activity.
Prescribing in practice
- High-dose pulses can cause serious acute effects including hyperglycaemia, hypertension, fluid retention, infection risk and, rarely, arrhythmia, so patients require close monitoring during and after infusion.
- Screen for and manage active infection before pulsing, and consider gastroprotection and bone protection as appropriate.
- It is given intravenously, usually over consecutive days, under specialist supervision.
Monitoring
Monitor blood pressure, blood glucose, fluid balance, electrolytes and for signs of infection during and following pulse therapy.
Counselling the patient
- You may notice flushing, a metallic taste, raised blood sugars or sleep disturbance around the infusions.
- Report fever or other signs of infection promptly, as steroids increase infection risk.
- Do not stop any prescribed continuing steroid abruptly without medical advice.
Evidence & guidelines
Pulsed methylprednisolone is a standard component of induction immunosuppression for severe ANCA-associated vasculitis and rapidly progressive glomerulonephritis.
Reference: KDIGO Vasculitis 2021; KDIGO Lupus Nephritis 2021; NICE NG232; SPC Solu-Medrone; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Steroid Conversion Calculator · Drug Dosing
- RCVS₂ Score for RCVS vs CNS Vasculitis · Stroke
- Kawasaki Disease Diagnostic Criteria · Paediatric Infectious Disease
- Kawasaki Disease Diagnostic Criteria · Inflammatory
- Kawasaki Disease Diagnostic Criteria · Kawasaki Disease
- KDIGO Heat Map for CKD Prognosis · Chronic Kidney Disease
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019